Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IONS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Part… NCT07727538 · Familial Chylomicronemia Syndrome Olezarsen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Recruiting | 12 | Aug 2030 | Registry ↗ |
| Nov 2, 2026 | A Study to Assess the Safety, Tolerability and Efficacy of ION775 NCT07604974 · Hypertriglyceridemia, Severe Hypertriglyceridemia ION775 | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Recruiting | 72 | Sep 2027 | Registry ↗ |
| Nov 2, 2026 | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome NCT07531745 · Dravet Syndrome ION337 | IONS Ionis Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | 32 | Dec 2030 | Registry ↗ |
| Nov 2, 2026 | Donidalorsen Treatment in Children With Hereditary Angioedema NCT07298447 · Hereditary Angioedema (HAE) Donidalorsen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Recruiting | 20 | Jun 2029 | Registry ↗ |
| Nov 2, 2026 | Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Peliz… NCT05659901 · Pelizaeus-Merzbacher Disease | IONS Ionis Pharmaceuticals, Inc. | — | Recruiting | 32 | Mar 2029 | Registry ↗ |
| Oct 20, 2026 | CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adult… NCT07782827 · Angelman Syndrome obudanersen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Recruiting | 30 | May 2028 | Registry ↗ |
| Oct 8, 2026 | ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Int… NCT06430385 · Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome ION440, Sham procedure | IONS Ionis Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | 48 | Sep 2027 | Registry ↗ |
| Sep 29, 2026 | Zilganersen Expanded Access Program for Individuals With Alexander Disease NCT07487389 · Alexander Disease zilganersen | IONS Ionis Pharmaceuticals, Inc. | — | Approved for marketing | — | — | Registry ↗ |
| Sep 29, 2026 | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome NCT06914609 · Angelman Syndrome obudanersen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 156 | Aug 2027 | Registry ↗ |
| Sep 18, 2026 | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION… NCT06153966 · Prion Disease ION717, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 1/2 | Active, not recruiting | 85 | Apr 2027 | Registry ↗ |
| Sep 14, 2026 | CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study NCT06073574 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Cardiac MRI | IONS Ionis Pharmaceuticals, Inc. | — | Completed | 160 | Mar 13, 2026 | Registry ↗ |
| Sep 11, 2026 | The CARDIO-TTRansform Scintigraphy Sub-study NCT06073587 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Scintigraphy scan | IONS Ionis Pharmaceuticals, Inc. | — | Completed | 163 | Mar 25, 2026 | Registry ↗ |
| Sep 4, 2026 | Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema NCT06415448 · Hereditary Angioedema Donidalorsen | IONS Ionis Pharmaceuticals, Inc. | — | Approved for marketing | — | — | Registry ↗ |
| Sep 3, 2026 | CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as IO… NCT04136171 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Eplontersen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | 1,438 | Mar 25, 2026 | Registry ↗ |
| Aug 21, 2026 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Dise… NCT04849741 · Alexander Disease zilganersen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 54 | Aug 22, 2025 | Registry ↗ |
| Aug 20, 2026 | HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Do… NCT05127226 · Angelman Syndrome ION582 | IONS Ionis Pharmaceuticals, Inc. | Phase 1/2 | Active, not recruiting | 71 | Mar 2029 | Registry ↗ |
| Jul 29, 2026 | A Non-interventional Cohort Safety Study of Patients With hATTR-PN NCT04850105 · Hereditary Transthyretin Amyloidosis With Polyneuropthy Data Collection | IONS Akcea Therapeutics | — | Active, not recruiting | 202 | Mar 31, 2036 | Registry ↗ |
| Jul 21, 2026 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 i… NCT04768972 · Amyotrophic Lateral Sclerosis ION363, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 89 | Jun 17, 2026 | Registry ↗ |
| Jul 9, 2026 | A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycyth… NCT05143957 · Phlebotomy Dependent Polycythemia Vera sapablursen | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 50 | Jun 26, 2025 | Registry ↗ |
| May 8, 2026 | An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema NCT04307381 · Hereditary Angioedema Donidalorsen | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 20 | Jan 24, 2025 | Registry ↗ |
| Apr 27, 2026 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults W… NCT04165486 · Multiple System Atrophy ION464, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 1 | Recruiting | 40 | Sep 2027 | Registry ↗ |
| Apr 23, 2026 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and… NCT05355402 · Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease Olezarsen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 154 | Mar 22, 2023 | Registry ↗ |
| Apr 17, 2026 | An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated… NCT05667493 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Eplontersen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Enrolling by invitation | 1,400 | Aug 2029 | Registry ↗ |
| Apr 9, 2026 | Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl… NCT06014541 · Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | IONS Ionis Pharmaceuticals, Inc. | — | Terminated | 29 | Oct 7, 2025 | Registry ↗ |
| Feb 20, 2026 | Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics… NCT06673069 · Alzheimer Disease, Down Syndrome ION269 | IONS Ionis Pharmaceuticals, Inc. | Phase 1 | Terminated | 1 | Dec 3, 2025 | Registry ↗ |
| Feb 10, 2026 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Ca… NCT05610280 · Hypertriglyceridemia, Cardiovascular Diseases Olezarsen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | 1,478 | Aug 8, 2024 | Registry ↗ |
| Feb 10, 2026 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia NCT05079919 · Severe Hypertriglyceridemia Olezarsen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | 617 | Oct 22, 2024 | Registry ↗ |
| Dec 12, 2025 | Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecall… NCT06150716 · Pelizaeus-Merzbacher Disease ION356 | IONS Ionis Pharmaceuticals, Inc. | Phase 1 | Recruiting | 24 | Jun 2028 | Registry ↗ |
| Dec 12, 2025 | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment o… NCT05392114 · Hereditary Angioedema Donidalorsen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 154 | Dec 2026 | Registry ↗ |
| Dec 12, 2025 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chy… NCT05185843 · Familial Chylomicronemia Syndrome Olezarsen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 24 | Jun 2027 | Registry ↗ |
| Dec 12, 2025 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicro… NCT05130450 · Familial Chylomicronemia Syndrome Olezarsen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 60 | Feb 2028 | Registry ↗ |
| Dec 4, 2025 | A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, I… NCT05071300 · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Eplontersen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 151 | Aug 2029 | Registry ↗ |
| Dec 1, 2025 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Sever… NCT05681351 · Severe Hypertriglyceridemia Olezarsen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 885 | Mar 2027 | Registry ↗ |
| Oct 22, 2025 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia NCT05552326 · Severe Hypertriglyceridemia Olezarsen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | 446 | Dec 17, 2024 | Registry ↗ |
| Sep 23, 2025 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkin… NCT03976349 · Parkinson's Disease BIIB094, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 1 | Completed | 62 | Aug 12, 2024 | Registry ↗ |
| Aug 19, 2025 | TEGSEDI Pregnancy Surveillance Program NCT04270058 · Hereditary Transthyretin-mediated Amyloidosis With Polynero… inotersen | IONS Akcea Therapeutics | — | Not yet recruiting | 20 | Nov 15, 2030 | Registry ↗ |
| Apr 10, 2025 | A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult… NCT04306510 · Hereditary Transthyretin Amyloidosis With Polyneuropthy TEGSEDI | IONS Akcea Therapeutics | Phase 4 | Terminated | 8 | Mar 20, 2024 | Registry ↗ |
| Apr 8, 2025 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild… NCT03186989 · Mild Alzheimer's Disease IONIS MAPTRx, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 1 | Completed | 46 | May 12, 2022 | Registry ↗ |
| Mar 7, 2025 | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participan… NCT03815825 · Macular Degeneration, Geographic Atrophy IONIS-FB-LRx, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 332 | Apr 18, 2024 | Registry ↗ |
| Mar 6, 2025 | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LR… NCT05139810 · Hereditary Angioedema Donidalorsen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | 91 | Nov 9, 2023 | Registry ↗ |
| Mar 6, 2025 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial C… NCT04568434 · Familial Chylomicronemia Syndrome Olezarsen, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | 66 | Jul 14, 2023 | Registry ↗ |
| Feb 18, 2025 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participan… NCT04714320 · Hypertension Placebo, IONIS-AGT-LRx | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 160 | Jun 29, 2022 | Registry ↗ |
| Feb 18, 2025 | Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sap… NCT04059406 · Beta Thalassemia Intermedia sapablursen | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Terminated | 29 | Mar 28, 2023 | Registry ↗ |
| Jan 23, 2025 | A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complem… NCT04014335 · Primary IgA Nephropathy IONIS-FB-LRx | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 23 | Feb 8, 2024 | Registry ↗ |
| Dec 27, 2024 | Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) NCT06360237 · Familial Chylomicronemia Syndrome Olezarsen | IONS Ionis Pharmaceuticals, Inc. | — | Approved for marketing | — | — | Registry ↗ |
| Dec 13, 2024 | NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION… NCT04136184 · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Inotersen, Eplontersen | IONS Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | 168 | Apr 11, 2023 | Registry ↗ |
| Nov 27, 2024 | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 NCT04932512 · Steatohepatitis, Nonalcoholic ION224, Placebo | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 160 | Jan 10, 2024 | Registry ↗ |
| Oct 31, 2024 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma NCT04398485 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma ION251 | IONS Ionis Pharmaceuticals, Inc. | Phase 1 | Completed | 23 | Sep 30, 2024 | Registry ↗ |
| Oct 3, 2024 | A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients… NCT04522180 · Acromegaly GHR-LRX | IONS Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | 34 | Jul 15, 2022 | Registry ↗ |
| May 10, 2024 | A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two… NCT05579860 · Healthy Participants Olezarsen | IONS Ionis Pharmaceuticals, Inc. | Phase 1 | Completed | 104 | May 22, 2023 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances